Cardiovascular Clinical Studies

This channel includes news and new technology innovations from cardiovascular clinical trials. These clinical studies include all cardiac subspecialties.

Alex Carll, assistant professor in the UofL Department of Physiology, front, with Matthew Nystoriak, associate professor of medicine. (UofL Photo)

News | Atrial Fibrillation

UofL Researchers Discover E-Cigarettes Cause Cardiac Arrhythmias

October 26, 2022 — A new study from University of Louisville researchers in the Christina Lee Brown Envirome Institute ...

October 26, 2022

Analysis of randomized controlled trial data shows non-Caucasian high-risk PCI patients significantly benefit from Impella-support

News | Intra-Aortic Balloon Pumps (IABP)

Abiomed Creates Patient Assistance Program to Address Disparities in Healthcare

October 26, 2022 — Abiomed (Nasdaq: ABMD) announces a new program to address healthcare disparities in underserved ...

October 26, 2022

Acutus Medical, Inc, an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated announced submission of pivotal clinical data from the AcQForce Flutter trial

News

Acutus Medical Announces Submission of Premarket Approval Application for AcQBlate Force Sensing Ablation Catheter and System

October 24, 2022 — Acutus Medical, Inc, an arrhythmia management company focused on improving the way cardiac ...

October 24, 2022

CinCor Pharma, Inc. announced the publication of Phase 1 clinical data for baxdrostat, a highly selective, once daily, oral small molecule inhibitor of aldosterone synthase, in the journal Hypertension Research.

News | Hypertension

CinCor Pharma Announces Publication of Phase 1 Multiple Ascending Dose Study Data in Hypertension Research

October 24, 2022 — CinCor Pharma, Inc. announced the publication of Phase 1 clinical data for baxdrostat, a highly ...

October 24, 2022

Abiomed announced the U.S. Food and Drug Administration (FDA) has accepted and closed the post-approval study reports related to the pre-market approvals (PMA) for Impella heart pumps.

News | Cardiogenic Shock

Abiomed Successfully Completes All Impella Post-Approval Studies for High-Risk PCI, Cardiogenic Shock, Post-Cardiotomy Cardiogenic Shock and Right Heart Failure

October 21, 2022 — Abiomed announced the U.S. Food and Drug Administration (FDA) has accepted and closed the post ...

October 21, 2022

People with cardiovascular disease still have a high burden of risk factors for severe COVID

News | Coronavirus (COVID-19)

Smoking, Diabetes and Obesity - Not Preexisting Heart Disease - Bigger Risk of COVID-19 Death, Study Finds

October 17, 2022 — A national study suggests that risk factors for cardiovascular disease, such as age, smoking and ...

October 17, 2022

Significant findings from the highly-anticipated EPIC-STEMI study were presented during a late-breaking scientific session at the recent Transcatheter Cardiovascular Therapeutics (TCT) 2022 Annual Symposium in Boston, MA.

Feature | TCT | Christine Book

Dramatic Cholesterol Reduction from PCSK9 Inhibitor Achieved in EPIC-STEMI Trial

October 17, 2022 — Significant findings from the highly-anticipated EPIC-STEMI study were presented during a late ...

October 17, 2022

The HELIOSTAR Balloon Ablation Catheter's unique one-shot balloon technology enables pulmonary vein isolation in 12 seconds, with customized energy delivery and one integrated 3D mapping solution

News | EP Lab

Biosense Webster Launches HELIOSTAR in Europe, the First Radiofrequency Balloon Ablation Catheter, Enabling Physicians to Perform More Efficient Cardiac Ablations

October 14, 2022 — Biosense Webster, Inc., part of Johnson & Johnson MedTech†, today announced the European launch of ...

October 14, 2022

Heart Initiative, the sponsor of the STRONG-HF (Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP testinG, of Heart Failure therapies) study, announced the premature termination of the trial.

News | Cardiovascular Clinical Studies

STRONG-HF Study in Patients Admitted for Acute Heart Failure (HF) Terminated Early for Superior Efficacy

October 14, 2022 — Heart Initiative, the sponsor of the STRONG-HF (Safety, Tolerability and efficacy of Rapid ...

October 14, 2022

The data, collected during the transition from intravenous (IV) to oral levosimendan in the open-label extension (OLE) of the HELP (Hemodynamic Evaluation of Levosimendan in PH-HFpEF) trial, were presented at the Heart Failure Society of America (HFSA) Scientific Sessions 2022

News | Heart Failure

Positive Data Presented at HFSA Annual Meeting Demonstrate Effects of Oral Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

October 13, 2022 — Tenax Therapeutics, Inc., a specialty pharmaceutical company focused on identifying, developing, and ...

October 13, 2022

the U.S. Patent and Trademark Office has issued to the University of Iowa Research Foundation ("UIRF") U.S. Patent No. 11,414,704 titled COMPOSITIONS AND METHODS FOR DETECTING PREDISPOSITION TO CARDIOVASCULAR DISEASE, which is exclusively licensed to the Company from UIRF

News | Heart Failure

Cardio Diagnostics Announces Issuance of U.S. Patent for Compositions and Methods for Detecting Predisposition to Cardiovascular Disease

October 13, 2022 — Cardio Diagnostics, Inc. , a pioneering precision cardiovascular testing company, announced that the ...

October 13, 2022

Zach Williams wanted to be a cancer researcher, but quick success in another area refocused his research on cardiovascular science. He was awarded a National Institutes of Health grant to fund his research for two years. Image courtesy of Clayton Metz/Virginia Tech.

News | Heart Failure

Virginia Tech Graduate Student Earns NIH Support to Explore Promising Heart Finding

October 13, 2022 — Zach Williams thought he’d become a cancer researcher when he joined Virginia Tech’s Translational ...

October 13, 2022

Videos | TCT

VIDEO: 3-Year Follow-up of the SYMPLICITY HTN-3 Trial

At TCT 2022, Deepak Bhatt, MD, MPh, Executive Director of Interventional Cardiovascular Programs, Brigham and Women's ...

October 13, 2022

The Delphi study results show Philips’ integrated echocardiography solution provides the tools required for baseline risk stratification and monitoring of cardio-oncology patients as recommended by the latest European Society of Cardiology (ESC) guidelines

News | Heart Failure

Panel of Experts Highlights Clinical and Operational Benefits of Philips’ Integrated Echocardiography Solution

October 12, 2022 — Following the recent European Society of Cardiology (ESC) Congress in Barcelona, Spain last month, ...

October 12, 2022

Study investigates metformin and other candidate drugs through a network medicine approach

News | Heart Failure

Cleveland Clinic Researchers Identify Diabetes Drug Metformin as Potential Atrial Fibrillation Treatment in Collaborative Research

October 12, 2022 — Cleveland Clinic researchers have identified a common diabetes medication, metformin, as a possible ...

October 12, 2022